Our editorial team dives into the pharma industry's reaction to US tariffs on imports from the European Union and major trends from Q2 earnings calls.

Sartorius has agreed to invest $3m in Nanotein Technologies, engaged in the development of advanced immune cell activation reagents.

PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates moving forward.

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.

As tariffs on drug imports from the EU look set to alter pricing and manufacturing strategies, each entity needs to study its full impact.

Biostar Stem Cell Technology Research Institute has received Japan's MHLW approval for its angel stem cell therapy for ASD.

Boehringer's Hernexeos is now FDA-approved for patients with HER2-positive NSCLC, bringing it into direct competition with ADC Enhertu.

Arvinas, in collaboration with Pfizer, has announced vepdegestrant NDA acceptance by the FDA for breast cancer treatment.

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act.

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.